Biological agriculture company advances manufacturing expansion to support rising U.S. demand while strengthening operational efficiency
MustGrow Biologics Corp., a developer of biological and regenerative agriculture solutions, reported improved operational performance for the first quarter ended March 31, 2026, supported by initial commercial sales of its TerraSante product portfolio, stronger gross margins and continued cost discipline.
The company generated $0.1 million in TerraSante sales revenue during the quarter, marking a significant step forward from the corresponding period in 2025 when no revenue was recorded from the product line. Gross margin on TerraSante products improved to 23.6 per cent, up from 19.5 per cent in the previous year, reflecting enhanced operational efficiency and product economics.
MustGrow also reported a reduction in expenses from continuing operations, which declined to $0.9 million during the quarter compared with $1.2 million in the same period last year. The company’s net loss narrowed to $1.3 million, improving from $1.6 million reported a year earlier.
As of March 31, 2026, MustGrow held $0.4 million in cash and cash equivalents, while maintaining working capital of $1.5 million, providing financial flexibility as it advances commercialisation efforts.
The company indicated that the quarter was characterised by significant manufacturing expansion activities among its contract production partners. Capacity enhancement initiatives aimed at supporting anticipated demand resulted in a temporary transition from batch-based production systems to dedicated continuous manufacturing lines capable of higher-volume output.
While these manufacturing adjustments created short-term production disruptions that extended into the second quarter, the company expects the expanded infrastructure to significantly strengthen its ability to fulfil customer orders and support accelerating demand for biological crop solutions across the United States market.
MustGrow’s latest results reflect a broader strategic focus on scaling commercial operations, improving manufacturing efficiency and expanding market penetration within the rapidly growing biologicals and regenerative agriculture sector. The company continues to position itself to capitalise on increasing farmer interest in sustainable crop protection and soil health solutions as agriculture transitions toward lower-input production systems.
